PMID- 26597813
OWN - NLM
STAT- MEDLINE
DCOM- 20161213
LR  - 20181202
IS  - 0317-1671 (Print)
IS  - 0317-1671 (Linking)
VI  - 43
IP  - 2
DP  - 2016 Mar
TI  - Adverse Clinical Effects of Botulinum Toxin Intramuscular Injections for 
      Spasticity.
PG  - 298-310
LID - 10.1017/cjn.2015.314 [doi]
AB  - OBJECTIVE: The adverse events (AEs) with botulinum toxin type-A (BoNTA), used for 
      indications other than spasticity, are widely reported in the literature. 
      However, the site, dose, and frequency of injections are different for spasticity 
      when compared to the treatment for other conditions and hence the AEs may be 
      different as well. The objective of this study was to summarize the AEs reported 
      in Canada and systematically review the AEs with intramuscular botulinum toxin 
      injections to treat focal spasticity. METHODS: Data were gathered from Health 
      Canada (2009-2013) and major electronic databases. RESULTS: In a 4 year period, 
      285 AEs were reported. OnabotulinumtoxinA (n=272 events): 68% females, 53% 
      serious, 18% hospitalization, and 8% fatalities. The type of AEs reported were - 
      muscle weakness (19%), oropharyngeal (14%), respiratory (14%), eye related (8%), 
      bowel/bladder related (8%), and infection (5%). IncobotulinumtoxinA (n=13): 38% 
      females, 62% serious, and 54% hospitalization. The type of AEs reported were - 
      muscle weakness (15%), oropharyngeal (15%), respiratory (38%), eye related (23%), 
      bowel/bladder related (15%), and infection (15%). Commonly reported AEs in the 
      literature were muscle weakness, pain, oropharyngeal, bowel/bladder, blood 
      circulation, neurological, gait, and respiratory problems. CONCLUSION: While 
      BoNTA is useful in managing spasticity, future studies need to investigate the 
      factors that can minimize AEs. A better understanding of the underlying 
      mechanisms of the AEs can also improve guidelines for BoNTA administration and 
      enhance outcomes.
FAU - Phadke, Chetan P
AU  - Phadke CP
AUID- ORCID: 0000-0003-0957-7941
AD  - 1Spasticity Research Program,West Park Healthcare Centre,University of 
      Toronto,Toronto,Ontario,Canada.
FAU - Balasubramanian, Chitra K
AU  - Balasubramanian CK
AD  - 4Clinical & Applied Movement Sciences,Brooks College of Health,University of 
      North Florida,Florida,USA.
FAU - Holz, Alanna
AU  - Holz A
AD  - 1Spasticity Research Program,West Park Healthcare Centre,University of 
      Toronto,Toronto,Ontario,Canada.
FAU - Davidson, Caitlin
AU  - Davidson C
AD  - 1Spasticity Research Program,West Park Healthcare Centre,University of 
      Toronto,Toronto,Ontario,Canada.
FAU - Ismail, Farooq
AU  - Ismail F
AD  - 1Spasticity Research Program,West Park Healthcare Centre,University of 
      Toronto,Toronto,Ontario,Canada.
FAU - Boulias, Chris
AU  - Boulias C
AD  - 1Spasticity Research Program,West Park Healthcare Centre,University of 
      Toronto,Toronto,Ontario,Canada.
LA  - eng
PT  - Journal Article
DEP - 20151124
PL  - England
TA  - Can J Neurol Sci
JT  - The Canadian journal of neurological sciences. Le journal canadien des sciences 
      neurologiques
JID - 0415227
RN  - 0 (Neuromuscular Agents)
RN  - EC 3.4.24.69 (Botulinum Toxins, Type A)
RN  - EC 3.4.24.69 (incobotulinumtoxinA)
SB  - IM
MH  - Botulinum Toxins, Type A/*adverse effects
MH  - Canada
MH  - Female
MH  - Humans
MH  - Injections, Intramuscular
MH  - Male
MH  - Muscle Spasticity/*drug therapy
MH  - Neuromuscular Agents/*adverse effects
MH  - Retrospective Studies
OTO - NOTNLM
OT  - adverse effects
OT  - botulinum toxin
OT  - dysphagia
OT  - muscle weakness
OT  - pain
OT  - spasticity
OT  - systematic review
EDAT- 2015/11/26 06:00
MHDA- 2016/12/15 06:00
CRDT- 2015/11/25 06:00
PHST- 2015/11/25 06:00 [entrez]
PHST- 2015/11/26 06:00 [pubmed]
PHST- 2016/12/15 06:00 [medline]
AID - S0317167115003145 [pii]
AID - 10.1017/cjn.2015.314 [doi]
PST - ppublish
SO  - Can J Neurol Sci. 2016 Mar;43(2):298-310. doi: 10.1017/cjn.2015.314. Epub 2015 
      Nov 24.